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The following review summarizes the state of the art in representative aspects of gene
therapy/translational medicine and evolves from a symposium held at the School of
Veterinary Medicine, University of Pennsylvania on November 16, 2017 honoring Dr.
Gustavo Aguirre, recipient of ARVO’s 2017 Proctor Medal. Focusing on the retina,
speakers highlighted current work on moving therapies for inherited retinal
degenerative diseases from the laboratory bench to the clinic.
Defining the Inherited Retinal
Dystrophy Genome
Professor Alison J. Hardcastle
Abstract: Inherited retinal dystrophies display re-
markable genetic heterogeneity, reflecting the com-
plexity of retinal structure and function. Next-
generation sequencing technologies have transformed
our ability to identify mutation-causing diseases but
also present additional challenges of interpreting
exome and genome variants as potentially patholog-
ical or benign. Nevertheless, next-generation sequenc-
ing offers the opportunity to reveal the unusual and
unexpected, such as expansion of phenotypes associ-
ated with specific genes, unexpected inheritance
patterns and aberrant splicing, which is emerging as
a relatively common mechanism of disease resulting
from introduction of cryptic exons, and rare combi-
nations of single-nucleotide polymorphism haplo-
types. As a complementary approach to developing
animal models to study disease mechanisms and test
potential mutation-specific therapies, we can differ-
entiate pluripotent stem cells to retinal pigment
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epithelium and optic cup organoids with mutations in
human genomic and cellular context, another very
useful tool in the study of inherited retinal degener-
ations.
The first gene mutation causing an inherited retinal
degeneration was reported in the rhodopsin gene in
1990.1 Linkage studies and Sanger sequencing of
candidate genes were instrumental in these early
analyses, but the completion of the human genome
sequence and next-generation sequencing (NGS)
technologies has accelerated the rate of discovery.
Today, over 280 retinal disease genes have been
mapped and/or identified (Fig. 1). These retinal gene
mutations lead to many different types of retinal
dystrophy, including Leber congenital amaurosis
(LCA), which affects rod and cone photoreceptors,
cone-specific diseases, such as achromatopsia, macu-
lar degeneration, such as Stargardt disease, and rare
syndromic diseases, such as Usher Syndrome and
Bardet-Biedl Syndrome. Mutations in a diverse
number of genes can lead to a similar disease
phenotype; for example, at least 14 genes have been
identified whose phenotypic characteristics fall within
the LCA classification. NGS has accelerated this gene
discovery process, but this also presents challenges in
interpreting potentially pathogenic variants compared
with benign variants. Specifically, whole-exome se-
quencing, which will sequence all protein coding parts
of genes (~20,000 genes), can identify genetic causes
in approximately 60% of cases. However, all 3 billion
nucleotides can now be sequenced using whole-
genome sequencing (WGS), but it can be very
challenging to identify a causative mutation as WGS
uncovers approximately 5 million differences in an
individual compared with the reference human
genome. Nevertheless, NGS has provided an unbiased
opportunity to reveal unusual and unexpected phe-
notypic associations, inheritance patterns, and genetic
mechanisms of disease (see examples below). Finally,
animal models of retinal degeneration, particularly in
the dog, have been instrumental in studying orthol-
ogous human retinal degenerations. For example, in
XLPRA,2 physical mapping of the canine genome,
linkage mapping and cloning with characterization of
the RPGR gene, led to the identification of the
causative RPGR variants in different dog breeds and
finally to gene therapy.3 Several canine disease models
have been developed by the Aguirre group, including
models of photoreceptor dysplasia (1998), RPE65-
based childhood blindness (2001), and achromatopsia
(2002); stationary night blindness has even been
studied in the Appaloosa horse (1978).
As mentioned above, NGS is a very valuable tool
in studying retinal degenerations because it is
unbiased and allows for all possible inheritance
modes to be considered for association of gene
variants with novel phenotypes. A good example of
Figure 1. Mapped and identified retinal disease genes. Figure modified from RetNet (in the public domain, https://sph.uth.edu/retnet)
to highlight landmark time points in path to disease gene discovery.
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this is the study of missense variants in the X-linked
gene PRPS1, which can cause retinal degeneration in
females.4 These patients show a type of retinitis
pigmentosa (RP) with tapetal-like reflexes and
patchy retinal atrophy. Missense mutations in
PRPS1 can have multiple effects, causing Arts
Syndrome, X-linked Charcot-Marie Tooth 5, and
X-linked nonsyndromic deafness. The absence of
affected males in the RP families suggests some
PRPS1 variants may be embryonic male lethal when
inherited in the hemizygous state. In another family
consistent with X-linked inheritance, no causative
variants on the X-chromosome were found; however,
two potentially deleterious compound heterozygous
variants were detected in two autosomal recessive
genes, indicating two recessive conditions in different
branches of the family. Similarly, linkage analyses
and NGS can uncover new loci and genes for
genetically heterogeneous diseases. For example,
the identification of the mutation responsible for
the RP23 locus for X-linked RP5 was possible
through targeted genomic NGS that revealed a deep
intronic mutation in OFD1.6 Point mutations in the
coding region and splice sites of OFD1 cause
ciliopathies, including male-lethal orofaciodigital
syndrome 1, Simpson-Golabi-Behmel syndrome,
type 2, and Joubert syndrome. Interestingly, RP23
is not male lethal; lower levels of transcript are
present, perhaps producing enough normal protein
for other ciliated tissues, but not the retina.
Approximately 8% of human males have a color
vision deficit, estimated at 250 million world wide.
The long wavelength (LW) and medium wavelength
(MW) cone opsins are highly homologous and share
98% identity at the nucleotide level. Recombination
between LW and MW genes creates a variety of
mutations and can also result in combinations of
polymorphic variants in exon 3. Mutations in the
OPN1LW (LW) and OPN1MW (MW) cone opsin
genes can lead to a wide array of cone photoreceptor
abnormalities, including progressive retinal degener-
ation. Genotypes can be clustered into the following 3
types: (1) deletions of the locus control region, (2)
inactivating mutations, and (3) exon 3 single-nucleo-
tide polymorphism (SNP) interchange haplotypes.
Some mutations can cause blue cone monochromacy
with no, or very slow progression, or are associated
with a diagnosis of progressive cone dystrophy.
Interestingly, in vitro splicing assays have shown that
interchange haplotypes, which in isolation would not
be considered to be detrimental to cone opsin
function, affect splicing, causing skipping of exon
3.7 All in all, it is clear that mutations in the LW and
MW cone genes can lead to a wide variety of
dystrophies ranging from simple color blindness to
severe cone cell dystrophies.
Along with mutant gene discovery and character-
ization, drugs and small molecules targeting specific
gene mutations, such as translational read-through
(TR-T) drugs, can be used in therapy. An example is
the case of mutations in the RP2 gene, which leads to
vision loss in a form of X-linked RP, and is often
affected by nonsense mutations. Patient fibroblasts
and iPSC-derived retinal pigment epithelial (RPE)
cells from a patient with the R120X mutation lack
RP2 protein, but, using translational read-through-
inducing drugs, up to 20% of normal RP2 protein can
be restored8 with reversal of cellular phenotype
defects. This suggests that the TR-T drugs could be
tested clinically for the restoration of vision in some
RP2 patients with nonsense mutations. In a similar
manner, specific gene mutations can be studied in
patient iPSC-derived RPE and optic cups in genomic
and cellular context, providing a model system to test
disease mechanisms and potential therapies. In optic
cups, not only can the underlying defects be
identified, but corrective measures can also be
designed and tested. Three-dimensional optic cups
from iPSCs carrying a CEP290 mutation that causes
LCA revealed that the optic cups have higher levels of
aberrant splicing caused by the intronic mutation
leading to fewer and shorter photoreceptor cilia.
When the optic cups were treated with an antisense
morpholino, aberrant splicing is blocked and full-
length CEP290 was generated,9 leading to a 5-fold
increase in the correctly spliced mRNA in the
CEP290-LCA optic cups. Thus, personalized models,
such as these optic cups as well as advanced molecular
biology techniques, can lead to a better understanding
of disease mechanisms as well as delivering therapeu-
tic insights.
Conclusions and Future Directions
 NGS helps us understand disease mechanisms
resulting from factors, such as introduction of
cryptic exons and rare combinations of SNP
haplotypes. It is a complementary approach to
developing animal models to study disease.
 We also can differentiate pluripotent stem cells
into RPE cells and optic cup organoids with
mutations in human genomic and cellular
context. This is another useful tool in the study
of the mechanisms of inherited retinal degener-
ations.
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Thoughts on Human Ocular Gene
Therapy: The Retinoschisis Gene
Therapy Clinical Trial
Dr. Paul A. Sieving
Abstract: Successful retinal pigment epithelial (RPE)
gene therapy for Leber congenital amaurosis (LCA)
in 2008 demonstrated therapeutic proof-of-concept
for treatment of human retinal degenerations. For the
RPE65-LCA trial, the vector is delivered by a
subretinal surgical approach, which treats a delimited
area. Intravitreal injection would be preferred for ease
of administration and to reach a wide expanse of
retina. Unfortunately, current vectors do not readily
penetrate into the retina. We are exploring the use of
intravitreal application of vector for a gene therapy
trial of X-linked retinoschisis (XLRS; Clinical tri-
als.Gov #NCT02317887). The photoreceptor electro-
retinogram (ERG) a-wave is characteristically normal
in XLRS but the postsynaptic bipolar cell B-wave is
depressed. We have evidence that the retinoschisin
(RS1) extracellular matrix protein is essential to
maintain synaptic integrity of rod photoreceptor
signaling onto bipolar cells. Hence, XLRS can be
considered a synaptic disease. Adeno-associated virus
(AAV)-RS1 gene therapy in XLRS retinoschisis
knockout (RSI-KO) mice closes the schisis cavities
seen in XLRS patients, improves synaptic function,
and increases the ERG b-wave. Our clinical trial
addresses whether this benefit extends to human
vision. Gene replacement therapy for monogenic
disease is simple in concept but implementation is
not necessarily straight forward. Critical factors in
AAV vector capsid biology that warrant attention are
as follows: (1) vectors that can penetrate into the
retina after intravitreal delivery, (2) increased trans-
duction targeting and efficiency, and (3) lower
immunogenicity. The field is moving forward at a
deliberate pace through this and other ocular gene
therapy trials that are underway.
Why gene therapy of the eye? To start with,
inherited retinal disorders affect 1 in 3000 individuals
around the world. They can cause progressive vision
loss and blindness, which can even be apparent from
early age as in Leber congenital amaurosis (LCA).
Inherited retinal disorders are the most common
cause of visual impairment registration in the United
Kingdom among working age individuals and second
in childhood. There are both personal and societal
reasons for addressing this problem, not least of
which involve the medical costs and the loss of
productivity due to loss of vision. The eye is well
suited for gene therapy, as it is a small, closed
compartment that allows for targeted delivery to the
retina. Thus, only small quantities of vector are
needed for treatment. Further, the eye is relatively
immune privileged so there is limited risk of systemic
toxicity. Animal models exist for many of the
inherited retinal diseases, and the cell types in the
eye are evolutionarily conserved from mouse to
human. Optical transparency of the eye allows for
safe, noninvasive retinal imaging in vivo. Finally, the
contralateral untreated eye can serve as a convenient
and effective control.
Following the lead of the LCA clinical trials for
mutations of the RPE65 gene, there are currently a
number of gene therapy clinical trials in progress on
different forms of retinal degeneration (Table). These
range from types of rod-based diseases, such as
retinitis pigmentosa (RP) to diseases mainly affecting
the macula and cone cells (Stargardt disease), as well
Table. Representative Gene Therapy Clinical Trials
Disease Target Viral Vector
Leber congenital amaurosis – LCA2 RPE65 AAV2
Retinitis pigmentosa (autosomal recessive) MERTK AAV2
Retinitis pigmentosa (X-linked recessive) RPGR AAV
Choroideremia REP1 AAV2
Stargardt maculopathy ABCA4 Lentivirus (StarGen; Sanofi, Paris, France)
Usher syndrome MYO7a Lentivirus (UshStat; Sanofi)
Leber hereditary optic neuropathy (LHON) ND4 AAV2a, AAV2tYFa
Achromatopsia CNGA3 / CNGB3 AAV8 / AAV2tYF
X-linked retinoschisis RS1 AAV8a, AAV2tYFa
a Administered by intravitreal application.
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as conditions, such as XLRS, which involve progres-
sive impairment of retinal synaptic function. Mostly,
AAV viral vectors have been used (AAV2, AAV8) to
deliver the normal gene replacement although lenti-
virus also appears to be an effective vehicle. The route
of administration is also under study (i.e., subretinal
versus intravitreal delivery).
Mutation of the RS gene is causative for XLRS
and results in reduction or elimination of the RS
protein. Immunolabelling reveals that the retinoschi-
sin protein is found in two prominent locations in the
retina, around the rod inner segments and around the
rod-bipolar synapses. More specifically, it is an
extracellular matrix protein with high lipid affinity
and coats the rod inner segments, although it is not an
integral membrane protein. Electron microscopy
(EM) immunogold-histochemistry shows RS protein
within the synaptic cleft between rod and depolarizing
bipolar cells. Loss of RS protein possibly explains
why the XLRS problem involves deficient activity
postsynaptic to the photoreceptor. At the molecular
level, cryo-EM three-dimensional imaging shows
back-to-back RS protein rings with eight RS proteins
aggregated into a planar disc and two octomers
forming a bilayer complex.10 Octomer-octomer con-
tacts may couple neighboring cell membranes, pro-
moting cellular adhesion; loss of RS1 would lead to
the disease-characteristic schisis cavities. All in all, a
‘‘Velcro Zipper Model’’ may explain one action of the
RS protein.
The prevalence of XLRS is approximately 1 in
5000 to 1 in 25,000 depending on the particular
population examined. Vision loss can be accompanied
by strabismus, nystagmus, and amblyopia. Diagnosis
is both clinical examination and electrophysiology,
using techniques, such as optical coherence tomogra-
phy (OCT) and ERG. OCT reveals typical cystic
spaces within the retinal layers while dark-adapted
ERG analysis demonstrates a typical decrease or loss
of the b-wave amplitude relative to the a-wave. The
intraretinal splitting results from mutations in the RS
gene that cause decreased RS protein but the exact
mechanism is not yet understood. Good genetic
studies start with good genetic pedigrees, and we
were fortunate at the University of Michigan to have
an extensive pedigree of XLRS and to collect blood
samples from 119 members of the family. In addition,
preclinical studies on gene therapy safety and efficacy
were facilitated by the construction of a RS1-KO in
our lab.11 In this model, the transgene construct
involved replacement of exon 1 by a neomycin
cassette and resulted in retinal structural disorgani-
zation, no RS protein detectable and functional loss
of the ERG b-wave implicating a synaptic deficit in
the absence of the RS protein. Problems in delayed
rod photoreceptor cell maturity as well as impaired
light-driven transducin translocalization have been
reported more recently.12 In this RS-KO model, we
initially performed gene therapy using an AAV(2/2)-
cytomegalovirus (CMV)-Rs1h vector containing
Rs1h cDNA with a CMV promoter. Subsequent
work expanded on these studies with an AAV8-RS1
vector restoring function and causing synaptic signal-
ing proteins to re-localize properly to the dendritic
tips of bipolar cells. This construct was injected into
the vitreous cavity of the XLRS mouse at 4 weeks of
age, and OCT and ERG studies were performed 12
weeks later. At that time, we found that the schisis
cavities were closed in the treated eyes, and the b-
wave had recovered (Fig. 2). Thus, such treatment
‘‘restored the normal ERG configuration,’’ demon-
strated safety and efficacy of the procedure and
allowing for movement toward a human clinical trial.
For the clinical trial, we developed the scAAV8-
hRS/interphotoreceptor retinoid-binding protein gene
(IRBP)-RS1 as the clinical vector (produced by Dr. J.
Fraser Wright at Children’s Hospital in Philadelphia,
PA). It is a nonpathogenic, replication-deficient AAV
sero-type 8 capsid containing the complete human
retinoschisis cDNA and a tissue-specific retinoschisis
promoter augmented by an IRBP enhancer element.
As demonstrated in the XLRS mouse, intravitreal
delivery of AAV8 RS reached the entire retina,13 and
distributed across all of the retina as seen histologi-
cally by 17 weeks of age. Importantly, cell-type
specific gene expression was seen with no ‘‘off-target
Figure 2. AAV-RS1 rescues structure and function in the XLRS
mouse. scAAV-hRS1/IRBP- hRS1 injected intravitreally at 4 weeks of
age and OCT and ERG evaluated 12 weeks later. Left panel
demonstrates that schisis cavities close. Right panel demonstrates
restoration of ERG b-wave (green arrow).
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expression.’’ A preclinical dose-escalation study of
intravitreal AAV8-RS1 gene therapy was performed
in the RS1-KO mouse for the Food and Drug
Administration (FDA) investigational new drug
(IND) application.14 With vector applied in mice at
4 weeks of age and analysis 12 weeks thereafter, a
dose-dependent expression was observed with im-
proved retinal structure and function at 13108 vector
genome copies per eye. Significantly, the study
indicated that a ‘‘fully normal level of RS1 expres-
sion’’ was not necessary for a therapeutic effect.
With this background, an application for an XLRS
gene therapy trial was made with FDA authorization
of the IND application in November of 2014,
registration with ClinicalTrials.Gov in December of
2014 and the first participant dosed with vector in
February 2015. Prior to this, however, important
matters needed to be considered in preparing for the
trial. What XLRS patient population should be used?
What are appropriate outcome measures, and what is
the reliability of those measures? In human XLRS,
there is a broad ‘treatment window of opportunity’
because the disease progresses to macular thinning
and atrophy during middle age. After age 45 to 50, the
schisis collapses and macular photoreceptors begin to
atrophy. The therapeutic outcome can be estimated
using visual acuity, full-field ERGs, microperimetric
macular visual sensitivity, and retinal thickness
measured by OCT. A test-retest intervisit variability
study was performed on seven participants in four
visits over a 6-month interval. We determined the 95%
confidence intervals for visual acuity, ERG measure-
ments, retinal sensitivity, and central retinal thickness
relative to baseline in the XLRS patients studied, and
thus these outcome measures are suitable for use in
the trial.15
At present, we are pursuing a human Phase I/IIa
trial of RS1 retinal gene therapy transfer for XLRS.
The study objective is to determine the safety,
tolerability, and biological activity of intravitreal
administration of gene transfer vector scAAV8-hRS/
IRBP-hRS to the retina of XLRS affected men. It is a
prospective, single-center (National Institutes of
Health), dose-escalation study using the AAV-RS1
vector administered in one eye by intravitreal
injection. The primary and secondary outcomes are
as follows: (1) adverse events that affect ocular
structure or function, (2) retinal structure changes as
determined by OCT, (3) retinal function changes as
determined by ERG response, (4) visual field sensi-
tivity as determined by MP-1 microperimetry, (5)
change of systemic blood chemistry parameters, and
(6) determination of circulating systemic anti-AAV8
antibodies. Study eyes received a dose of 1e11 vector
genomes per eye. In one participant, extensive
parafoveal schisis cavities were observed prior to
treatment with complete closure by 14 days after
vector administration.
Conclusions and Future Directions
With this good news, we can plan the next steps in
our XLRS trial.
 The dose range and number of participants can
be extended.
 We can plan to better understand the inflamma-
tory immune response.
 We seek to design measures to manage the acute
ocular inflammation observed. For the field
generally, there are areas that need further
development.
 Better vectors/synthetic capsids should be devel-
oped. In particular, we should develop intravit-
real vectors to enhance retinal delivery.
 Learn how to modulate the inevitable immune
response.
 Extend the durability of treatment benefit.
Beyond these factors, it should be remembered
that each disease has unique features to understand
and address. Outcome metrics must be tailored
specifically for each condition. Finally, we must
remember that, although patients are eager to
participate in clinical trials, it is critical to manage
their expectations.
Shooting in the Dark: Studies in Cone-
Targeted Therapies
Dr. Jose´-Alain Sahel
Abstract: We have started on a ‘‘fishing expedition’’
aiming at identifying the underlying mechanisms in
cone degeneration as potential clues for therapies that
preserve/restore light-adapted and central vision in
patients with retinal dystrophies. The discovery of
rod-derived cone viability factor (RdCVF), the
identification of its receptor and mechanism of action,
and the demonstration of its potential therapeutic
benefit in several animal models paved the way for
upcoming clinical trials. Emerging optogenetic strat-
egies are now under evaluation to restore cone or
inner retinal function. Selection of target populations
of patients that might benefit from these strategies
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will rely on in depth phenotyping, while demonstra-
tion of the therapeutic value will require the
development of novel, real life, functional outcome
measurements.
Pathologies with photoreceptor degeneration are
varied in type and number. Thirty million are
affected, including age-related macular degeneration,
with 10% to 20% severely impaired. Fewer are
affected with retinitis pigmentosa (RP; 1/4000 indi-
viduals) and allied diseases, but profound vision loss
and blindness is a common occurrence in these
pathologies, often from birth. Our goal is to provide
personalized therapies to all of these retinal dystro-
phies. Several of the following factors are involved in
this process:
1. identification and correction of the causative
gene defect
2. protecting the remaining photoreceptor cells
3. restoring light responses in the degenerated
photoreceptor or other retinal cells
4. restoring retinal encoding
5. determining the status of the remaining tissue
6. demonstrating the restoration of useful vision
The process starts with identification, character-
ization, and ultimate correction of causative gene
defects in the inherited retinal dystrophies. Once
identified and characterized, correction can take
several approaches, such as gene therapy or gene
editing. Recent achievements in gene therapy, include
progress in clinical trials for Leber congenital
amaurosis (LCA), choroideremia, retinoschisis,
achromatopsia, Stargardt disease, and Usher syn-
drome, with preclinical work on many disease-causing
genes, including PDE6 and RPGR. Nowhere is this
more important than in therapy for cones of the
macula, because these photoreceptors serve central,
sharp, and color vision. Gene replacement therapy
must be safe and functional but practical challenges
remain. There is, for example, a complexity and large
number of mutations responsible for the various
disease phenotypes—at least 63 genes identified for
RP alone, while many disease entities are yet caused
by unknown mutations. Planning for the clinical trial
can be a challenge not least of which is deciding on
the subject population and the stage of intervention.
Another challenge is to protect the remaining
photoreceptor cells. This is difficult because of the
intense remodeling of retinal tissue, including cell loss,
loss of conductivity, and glial proliferation,16 that
follow the sequential loss of rods and cones. In RP,
most mutations are rod-specific with initial loss of
rods followed by cones, giving a variable window of
time for cone-directed strategies. As has been stated
by Dr. Paul Sieving ‘‘50% cone loss is yet compatible
with an acuity of 20/20’’ and ‘‘95% cone loss is
compatible with a correct orientation and discrimi-
nation performance.’’17,18 Similarly, Dr. Alan Wright
has stated that ‘‘preserving cones would prevent 1.5
million people worldwide from becoming blind
because, in the age of artificial lighting, we function
very well without rods.’’19 One possible strategy for
cone rescue is through transplanting rods into the
degenerating retina. Many studies from our group
have demonstrated that cone survival is dependent on
the presence of rods and selective transplantation of
rods could slow the loss of cones, maintaining useful
vision in RP.
Such selective transplantation of rods that was
demonstrated to slow cone loss in RP models20 can
possibly maintain useful vision in humans through a
trophic activity exerted by a diffusible factor that
stimulates cone survival.21 This trophic factor was
identified as the rod- derived cone viability factor
(RdCVF)22 a protein encoded by the nucleoredoxin-
like-1 (Nxnl1) gene that also encodes the thioredoxin
enzyme rod-derived cone viability factor long
(RdCVFL). The cone-protective effect of RdCVF
has been found to be independent of the causative
gene, working both on autosomal recessive muta-
tions, such as in the rd1 mouse, and autosomal-
dominant diseases, such as in the P23H rat.
The mode of action of the NXNL1 gene product is
complex, involving stimulation of glucose metabolism
by RdDVF and repair of oxidative damage by
RdCVFL.23,24 RdCVF helps to preserve the mor-
phology of the cone outer segment by accelerated
glucose entry into photoreceptors and enhanced
aerobic glycolysis. In parallel, administration of the
enzymatically active RdCVFL reduces the damage
produced by photo-oxidative stress in the Nxnl1/
mouse, restoring cone function and viability toward
normal. These combined actions of RdCVF and
RdCVFL have therapeutic implications as, even with
significant reduction in visual acuity, theoretically,
they will allow for years of preservation of central
vision as outlined by Le´veillard and Sahel.25
Two other challenges are to restore light responses
of degenerated photoreceptor cells as well as restora-
tion of retinal encoding. Although optogenetics can
be used to insert photoswitches into retinal secondary
neurons after loss of photoreceptors, it can also be
used to reactivate ‘‘dormant’’ cones for restoration of
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visual responses. In mouse models of RP, the
expression of archaebacterial halorhodopsin in light-
insensitive cones can substitute for the native photo-
transduction cascade and ‘‘restore light sensitivity.’’26
In human ex vivo retinas, halorhodopsin can also
‘‘reactivate light-insensitive human photoreceptors’’
as demonstrated by the groups of Roska, Picaud, and
Sahel.26 Besides this application in cone photorecep-
tors, optogenetics can restore vision by using photo-
switches in secondary retinal neurons, which can
survive years after degeneration of photoreceptors in
RP patients. Targeting channelrhodopsin-2 to ON-
bipolar cells restores ON and OFF visual responses.27
This was done in rd1 blind mice through intravitreal
injection using adeno-associated virus (AAV) gene
therapy. A problem with optogenetics though is that
cells expressing the photoswitch proteins are less
sensitive to light, so vision under normal lighting
conditions would not be achieved. To address this
challenge, the company Gensight Biologics (Paris,
France) has a clever solution in their developmental
pipeline. In their technique, a red-shifted channelrho-
dopsin protein is first introduced into remaining
retinal neurons via a modified AAV vector (AAV2-
7m8). Biomimetic camera goggles then stimulate the
bioengineered retinal cells with images projected onto
the retina by a light source using a specific wavelength
(light-emitting diode light amplification). Functional
visual perception thus can be restored.
A fifth challenge involves determination of the
status of the remaining tissue. This is most important
in assessing foveal cone cells in late-stage RP and
reanimating them. Complete photoreceptor maps are
useful in these studies through fusion of images with
different entry points.
Finally, there must be a demonstration of the
restoration of useful vision. For this, we must get out
of our comfort zone of reliable, highly standardized,
precisely measured clinical tests into the messy world
of patient-reported outcomes questionnaires and
performance-based tests. Questions such as ‘‘Is a 1-
line acuity gain clinically meaningful and does it make
a difference to the patient?’’ should be asked. To
better answer these questions, we have designed the
Streetlab platforms at the Institut de la Vision that
provides ‘‘training, consulting and evaluation services
to companies that are developing products and
services improving autonomy, mobility, and quality
of life of visually impaired people’’. Three-dimension-
al simulators are used to simulate and evaluate low
vision. Also, an Artificial Street is simulated on an
indoor platform that has the appearance of an urban
area. There are behavioral recordings using a motion-
capture system (Vicon, Oxford, UK) with specific
markers, internal sensors, an eye tracker and surveil-
lance cameras. A control room is used for monitoring
and recording and there is postprocessing. Objective
behavioral measurements can be made: gate analysis,
for example, allows for measurement and analysis of
movement patterns, kinematics, and kinetics, as well
as forces produced by movements. Walking cycles can
be assessed as well as cycles affected by aging (e.g.,
shorter stride length) and low vision (e.g., longer
stance duration). Similarly, trajectory changes in
tunnel vision–RP patient head direction as well as
gaze behavior (head and eye orientation) can be
assessed.28
Conclusions and Future Directions
The following factors need to be addressed to
adequately provide effective, personalized therapies
for the diverse population of patients with inherited
retinal degenerations:
 identification and correction of the causative gene
defect
 protection of the remaining photoreceptor cells
 restoring light responses to the affected retina
 restoration of coding ability to the affected retina
 assessment of the status of the affected remaining
tissue
 demonstrating the restoration of functional vi-
sion
From Classifying Patterns of Visual
Loss to Planning Therapies:
Autosomal Dominant Retinitis
Pigmentosa Caused by Rhodopsin
Mutations
Dr. Samuel G. Jacobson and Dr. Artur V.
Cideciyan
Abstract:We are advancing from an era of description
of disease patterns in autosomal-dominant retinitis
pigmentosa (adRP) to a time of potential therapies.
To answer specific questions about how to administer
therapy, we reinvestigated the phenotype. We studied
adRP patients with rhodopsin gene mutations at
different disease stages to try to understand more
details of the disease expression in preparation for
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local and retina-wide therapies for the regionalized
retinopathy known as Class B phenotype. At least
three components of the phenotype were found in
these cross-sectional studies.
Although originally thought of as a single entity,
retinitis pigmentosa (RP) is now known to be a great
number of disease conditions caused by different
genetic mutations that lead to degeneration of retinal
photoreceptors and loss of vision. Treatment strate-
gies are beginning to be designed for these individual
conditions. This progress requires careful classifica-
tion and characterization of the disease entities both
genetically and phenotypically to ensure thorough
evaluation of any proposed therapy.
The first step in this process usually occurs in the
clinic with a history, pedigree, and examination. For
autosomal-dominant retinitis pigmentosa (adRP),
premolecular phenotyping led to the understanding
that there were two major forms.29,30 In Type 1 (Type
D), there is early-onset retina-wide diffuse and severe
loss of rod function with later loss of cone function.
Type 2 (Type R or sector RP) exhibits a milder
phenotype. Rod and cone function can be lost in one
retinal region but retained in the remaining regions. A
mutation in the rhodopsin (RHO) gene was the
earliest report of a cause for RP, specifically, adRP.
Over the years though, this complexity has increased
from one mutation to more than 100 mutations in the
RHO gene. The question then became ‘‘Was there any
way to make sense of the phenotypes of this large
number of RHO genotypes?’’ In the 1990s, many
investigators cataloged the subjective onset of night
blindness and the degree of rod dysfunction and
patterns of field loss in subjects carrying RHO
mutations. In 1998, we divided the RHO diseases
into two main phenotypic classes with accompanying
genotyping.31 Class A RHO mutants have severe,
early rod-cell loss with residual cone function
following normal cone density. Genotypes include,
for example, R135G, R135L, R135W, E181K,
V345L, and P347L mutations. Class B RHO mutants
exhibit slow loss of rod function in certain retinal
regions; cone function can remain normal until over
75% of rod outer segments are lost. Genotypes
include, for example, T17M, T58R, V87D, G106R,
D190G, and P23H mutations.
More recently, we examined a large cohort of
RHO Class B patients clinically, and with psycho-
physics and imaging (cross sectional and en face) at
different disease stages. As a consequence, we were
able to better describe the complexity of the Class B
phenotype.32 Patients could have hemifield dysfunc-
tion, pericentral loss of function, or a diffuse rod
sensitivity loss across the visual field. There could be
combinations of the different patterns. Photoreceptor
layer thickness measurements, co-localized with the
psychophysical data, were in agreement with these
patterns.
With this updated knowledge of genotyping and
phenotyping, attention can now turn to some very
practical questions about treatment of RHO muta-
tions, specifically therapy of Class B RHO mutants
with remaining rod vision and structure. For a local
(subretinal) therapy, is it best at a certain eccentricity?
Maybe just determine a transition zone from healthier
to unhealthier retina and inject there? This could be at
the in-out boundary at the edge of the ellipsoid zone
line of OCT? For a systemic therapy (e.g., oral) what
retinal regions should be monitored for efficacy? Is
there improvement? Lack of progression? Toxicity?
What disease stage should be monitored?
Conclusions and Future Directions
 There is a three-component pattern of visual loss
in Class B RHO patients.
 Whether focal or systemic treatment, we must
know which and how many of these patterns are
present in each patient and design the treatment
or monitoring accordingly.
 A ‘‘one-injection site fits all’’ protocol in a clinical
trial would seem to be the easiest treatment
delivery approach but, with what we now know,
this would be ill advised for Class B RHO
patients.
 For example, a macular, subretinal injection into
the cone-rich central retina is potentially risking
the 20/20 vision in this region and not serving the
purpose of trying to positively alter the natural
history of rod disease. Equally, an injection in an
inferior retinal area devoid of photoreceptors is
obviously ill conceived. Pretreatment mapping of
function and structure in this disease group is
needed to make enlightened decisions about
planning any therapeutic intervention.
Optogenetic Vision Restoration
Dr. John G. Flannery
Abstract: Electronic retinal prostheses can restore
useful vision in patients affected by retinal degener-
ations. Optogenetics is an alternative therapeutic
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approach. To date, however, a major limitation of the
microbial opsins used for restoration of retinal light
sensitivity in optogenetics is the high light intensity
required for activating channelrhodopsins. One solu-
tion to this caveat is the use of mammalian opsins
with higher light sensitivity but sufficiently fast
kinetics for useful motion vision. We are developing
a novel approach to restore vision to patients by
expressing light sensitive G-protein coupled receptors
(GPCR) proteins in specific, second-order retinal
neurons to make them light sensitive. Our approach
uses a common neuronal receptor, modified to add a
light receptive function to the remaining light-
insensitive retinal neurons that survive after photore-
ceptor degeneration. The receptor uses either retinal,
which is available in the eye or a synthetic chemical
photoswitch delivered by intravitreal injection. In this
way, the cells in which the receptor is located respond
to light with a change in neural firing. This
compensates for their loss of input from photorecep-
tors, restoring light responsiveness to the retina, and
sending information to the brain to restore vision. In
most cases, this approach is independent of the
mutation that causes the photoreceptor degeneration.
Exceptions to this approach may be diseases that
cause RPE dysfunction, such as Leber congenital
amaurosis (LCA) 2, or retinal pigment epithelial
(RPE) cell death as in choroideremia. To date,
versions of this approach, developed by our group
and others in the field, have employed receptors that
are rather insensitive to light or very slow in response
so could not support normal motion vision. We are
developing a new strategy that uses the natural
amplification properties of GPCR signaling to
increase sensitivity by 1000 times and response speed.
GPCR signaling cascades are intrinsic to rods and
cones as well as to bipolar, ganglion, and other retinal
cells. We are also pursuing a new discovery, a
combinatorial approach that uses more than one
optical sensor molecule at a time to recreate the
diversity of natural signaling in the retina that earlier
had been missing. We have employed sophisticated
behavioral analyses to test not only the restoration of
the ability to tell light from dark or flashing from
steady light but to determine if the animal is able to
see images.
Gene therapy for early-stage retinal diseases
primarily targets photoreceptors and RPE cells,
mainly through gene replacement therapy. Numerous
clinical trials are in progress, and one product
(voretigene neparvovec; Spark Therapeutics, Phila-
delphia, PA) has been approved by the Food and
Drug Administration for clinical use. In contrast,
gene therapy for late-stage retinal diseases (where
photoreceptors have been lost) targets bipolar and
retinal ganglion cells (RGCs), mainly using optoge-
netic techniques. Several companies are planning
clinical trials in this area. Acucela (Seattle, WA) is
investigating adeno-associated virus (AAV) vectors to
deliver human rhodopsin33,34 to ON-bipolar cells.
Allergan (Dublin, Republic of Ireland) has an
approach using channelrhodopsin-2 targeted to reti-
nal ganglion cells. Gensight (Paris, France) proposes
to use a red-shifted channelrhodopsin (ChrimsonR)
expressed in RGCs.
Delivery
The design of the viral vectors and their surgical
application varies between early- and late-stage gene
therapies. A major consideration in evaluating a
potential therapy in animal models is that the
tropism of a specific virus changes significantly
when applied in a different species. For example,
gene expression is restricted to macular RGCs in the
nonhuman primate (NHP) retina after intravitreal
injection of AAV serotype 2 while there is panretinal
expression in rodent RGCs with this vector. This is
largely due to the thicker inner limiting membrane
(ILM), posing a greater barrier to transduction from
the vitreous in NHP retina compared with rodents.35
AAV vectors efficiently transduce NHP RGCs in the
region of the macular pit, where the ILM is thinner,
but poorly transduce RGCs in the equatorial and
peripheral retina of NHP, due to the penetration
barrier of the ILM. This is not observed in rodents,
where the ILM is thinner throughout and much less
of a physical barrier to viral particles.36 In contrast,
intravitreal injection of AAV serotype 2 does not
efficiently transduce Mu¨ller glial cells in rodent or
NHP.37,38 AAV can access Mu¨ller cells from the
vitreous but glia lack the cell surface receptors
required for binding and internalizing most natural
AAV serotypes.37 Subretinal injection of AAV2
efficiently transduces photoreceptors and RPE cells
but not Mu¨ller glia. Neither route efficiently
transduces inner retinal neurons such as bipolar,
horizontal, and amacrine cells. We are developing
new AAV vectors with improved characteristics for
use in ophthalmology. We have applied a directed
evolution technique to identify AAV variants with
improved gene delivery to specific retinal cells
following intravitreal delivery.36 The intravitreal
route has significant advantages over subretinal
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injection, particularly for the central retina, as it
avoids detachment of the delicate macular and foveal
photoreceptors from the RPE.
Discovery and characterization of novel AAV
vectors was performed first in mouse retina,39 and
more recently in the retina of a dog and NHP. To
begin a ‘‘directed evolution’’ study, libraries of AAV
viruses are created by modifying the ‘cap’ gene that
encodes the three structural proteins that form the
AAV capsid. One type of library is made by using
error-prone polymerase chain reaction to introduce
random point mutations into the cap open reading
frame. Additional libraries are created by an in vivo
recombination method or cap gene shuffling, gener-
ating random chimeras of AAV cap genes, yielding
AAV libraries with millions of novel serotypes.
Testing in the dog (with Dr. William Beltran) has
been productive and has generated improved AAV
variants for transduction of canine retina. We
combined directed evolution with DNA-barcoded
vectors and deep sequencing to track the best
performing variants through successive rounds of
selection. We found that the AAV pool becomes
enriched for an increasingly small number of winning
AAV variants over successive rounds of selection.
Specifically, the application of barcoded AAV librar-
ies and deep sequencing identifies the best performing
variants in the outer nuclear layer and in RPE cells.
We are currently screening AAV libraries In NHP
retina through six rounds of screening following
intravitreal injections. In this way, new AAV capsid
variants specifically optimized for primates are
identified.
Application of New AAV Vectors to
Optogenetics
Current optogenetic approaches have been limited
by the fact that, although the naturally occurring
optogenetic molecules are extremely fast in their light
response, they are not very light sensitive. In addition,
unlike the retinal rod and cone photoreceptors, these
molecules cannot adapt their range or adjust their
sensitivity. As a result, their function is limited to 1 or
2 log units of illumination, and do not cover the many
(~11–12) log units of light intensities that encompass
natural scotopic and photopic vision (Fig. 3). One
design consideration is ‘‘How fast and how sensitive
does optogenetics for vision restoration need to be?’’
Our current goal is to restore useful motion vision at
normal lighting levels to blind patients. When
selecting a light-sensing molecule, physics imposes
an unavoidable tradeoff of light sensitivity versus
response speed. The ‘‘persistence of vision’’ phenom-
enon is exploited by cathode ray tube monitors to
make single pixels appear continuous when flickering
at 1/20 of a second. Light-emitting diode monitors
appear stable when illuminating a narrow strip at 60
Hz.
Optogenetic sensor proteins can be modified to
increase their sensitivity, but a system using a single
protein as sensor and effector will have a limited
range of adaptation. Optogenetic proteins, such as
channelrhodopsin (Chr2) and halorhodopsin
(NphR), are a ‘‘1-component’’ system—they func-
tion as both the light sensor and the ion channel
effector. A light sensitive ion channel, such as Chr2,
can have exceptionally fast responses in terms of
channel opening and closing in response to light,
well above 50 Hz, substantially faster than rod or
cone photoreceptors. One tradeoff for the high
response speeds is a small adaptation range. When
used in the retina, this will require the use of
electronic goggles to intensify the projected image
and to provide adaptation. It is useful to remember
that natural microbial switches, such as channelr-
hodopsin and halorhodopsin function in algae for
phototaxis, not vision. Melanopsin primarily plays a
nonimage-forming role in setting the circadian
rhythm. Other systems have been evaluated, such
as synthetic photoswitches (e.g., the ionotropic
glutamate receptor; LiGluR).40–42 This light-gated
ion channel is also ‘‘1-component’’ and similarly
Figure 3. Light sensitivity of natural and artificial photoreceptor
systems. Reprinted with permission from Gaub BM, Berry MH, Visel
M, Holt A, Isacoff EY, Flannery JG. Optogenetic retinal gene therapy
with the light-gated gpcr vertebrate rhodopsin. In: Boon C,
Wijnholds J, eds. Retinal Gene Therapy. Methods in Molecular
Biology. Humana Press: New York; 2018:177–189.
11 TVST j 2018 j Vol. 7 j No. 5 j Article 8
Hardcastle et al.
lacks the amplification and adaptation found in the
phototransduction cascade native to rod and cone
photoreceptors.43–47
We asked, ‘‘What are the advantages and
disadvantages of targeting different cell types in
the degenerating retina?’’ ON-bipolar cells, for
example, are one potential target for optogenetic
activation to treat blindness. They are upstream of
the RGCs, allowing the possibility to recapture
some of the intrinsic retinal image processing
functions of the retinal circuity. Retinal ganglion
cells are a more ‘down-stream’ target for late-stage
retinal disease.
In a 6-month-old photoreceptor-less rd1 mouse
retina that is insensitive to light, LiGluR gene
expression in RGCs elicits a strong light response.38
This restoration of light sensitivity was also seen with
LiGluR expression in ON-bipolar cells42; however,
there is more diversity in RGC responses driven by
ON-bipolar expression than by making all the RGCs
intrinsically light sensitive. In an alternative ap-
proach, rhodopsin can also be expressed ectopically
in ON-bipolar cells34 where it drives light responses in
blind rd-1 mouse retinas.
With rhodopsin, we employ a system more similar
to the native photoreceptor phototransduction cas-
cade, by separating the light sensor (rhodopsin) from
the ion channel effector with an interconnecting G-
protein coupled receptors (GPCR) cascade. This
approach gives 10003 higher sensitivity and adds
several log units of adaptation above the 1-compo-
nent approaches. However, we found that rhodopsin,
ectopically expressed in bipolar cells, responds to light
much more slowly than it does in rods. This response
is likely too slow for motion vision and may be due to
different G-protein cascades with slower kinetics in
bipolars than in photoreceptors. Searching for a
response speed more useable for vision in motion
for patients, we are currently testing cone opsin
responses in –ON bipolars.
We also studied whether combinations of genet-
ically and chemically engineered LiGluRs could be
useful in vision restoration. We previously found
that, in the rd1 mouse model, LiGluR ‘‘restores
light sensitivity to RGCs, reinstates light respon-
siveness to the primary visual cortex and restores
both the pupillary reflex and a natural light-
avoidance behavior.’’40 We extended this work to
investigate the possibility of combining LiGLuR
with the light-agonized and light-antagonized me-
tabotropic glutamate receptors (LimGluRs).48 In
this work, Levitz, et al., found that light-agonized
LimGluR2 was ‘‘fast, bistable and supported
multiple rounds of on/off switching.’’ We found
that AAV-SNAP-mGLUR2 expression in rd1
mouse RGCs endows a light-sensitive inhibitory
OFF-response. The treated animals could learn to
recognize an illuminated pattern on an organic
light-emitting diode display to avoid a mild foot
shock.
We then asked, ‘‘Can we express two optogenetic
switches with opposite response properties to restore
more complex vision?’’ For this, we co-expressed an
ON agonist and an OFF agonist in RGCs.
Functionally, we co-injected two AAV viral DNA
expression vectors, LiGluR and SNAP-mGluR2. A
random distribution of expression of two photo-
switches in RGCs was generated by the two AAV
vectors. We found that mice expressing either the
ON and theOFF sensor proteins could perform a
learned behavioral response requiring visual discrim-
ination of ‘þ’ versus ‘’ sign to avoid a mild foot
shock. Combined expression of the ON and OFF
response yields improved line discrimination behavior
over either sensor acting alone.
Conclusions and Future Directions
Optogenetics can provide useful vision restoration
for late-stage retinal degenerations:
 We can target proteins to specific retinal cell
classes using engineered AAV variants. The light-
sensitive proteins drive light responses in the
retina and enable innate and learned visually
guided behavior in mice.
 Expression of a light-activated On–transient ion
channel in –ON bipolar cells generates diverse
responses in ganglion cells, whereby expression
of a light-activated On–transient ion channel in
all functional subtypes of ganglion cells gener-
ates a uniform retinal output with little diversity.
 ‘‘One-component’’ light-sensitive ion channels
like channelrhodopsin and LiGluR are very fast
but not very light sensitive and provide very
limited adaptation range.
 Light-sensitive GPCRs like rhodopsin have in-
creased range of adaptation and increased sensi-
tivity but have slower responses than single-
component sensors like channelrhodopsin2 and
LiGluR when expressed ectopically in ON-
bipolar cells. This is likely due to the kinetics of
the G-protein cascade and ion channel ‘‘hijacked’’
in the bipolar cell.
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 Combinations of optogenetic sensors may be able
to restore pattern vision.
Preclinical Development of a Single
Vector Strategy for Rhodopsin
Autosomal Dominant Retinitis
Pigmentosa Gene Therapy
Dr. William A. Beltran
Abstract:Mutations in the rhodopsin (RHO) gene are
the most common cause of autosomal dominant
retinitis pigmentosa (adRP) and no treatment is
currently available. We have developed an allele-
independent single adeno-associated virus (AAV)
vector-mediated gene therapy strategy that combines
two important treatment aspects. First, knocking
down via shRNA technology the expression of
endogenous RHO, both wild-type (WT) and mutant
copies. Secondly, replacing endogenous RHO expres-
sion with that from a normal human RHO cDNA
made resistant to the shRNA via silent mutations.
This combined gene therapy approach was tested in
dogs that carry a mutation in RHO and show similar
features of disease as reported in Class B RHO-adRP
patients. Our results show successful and stable
prevention of disease onset in areas of the retina that
were treated.
Mutations in the rhodopsin (RHO) gene are a
common cause of autosomal-dominant retinitis pig-
mentosa (adRP) and constitute 30% to 40% of this
type of retinal degeneration (1/40,000). Over 150
different mutations in the RHO gene are known to be
responsible for adRP. Many of these result in a toxic
gain of function mechanism so are not amenable to
treatment by simple gene augmentation therapy. One
approach to this problem is to eliminate (knockdown)
endogenous production of rhodopsin, both the wild-
type (WT) and mutant alleles, and then replace them
with a WT RHO cDNA that has been modified to be
resistant to the knockdown tool (e.g., shRNA) and
results in the production of a normal RHO protein.
Certain dog breeds like the English mastiff in which a
form of retinal degeneration caused by a point
mutation, Thr4Arg (T4R), in the RHO gene are the
only naturally occurring animal models of RHO
adRP identified to this date.49 The phenotype,
characterized by a topographic pattern of disease
that affects primarily the central retina, closely mimics
the altitudinal distribution of disease reported in some
RHO-adRP patients. Besides its large (human-sized)
eye and the presence of a central bouquet of cone
photoreceptors similar to the fovea of the primate
that has a predilection for naturally occurring
inherited macular degenerations,50 a significant value
of the heterozygote RHO-adRP dog model is that it
expresses natural levels of both mutant and WT RHO
protein. This is extremely valuable for identifying the
optimal levels of RHO knockdown and replacement
that are necessary to correct, in particular, the
deleterious effects of toxic gain of function mutations.
Cideciyan et al.51 studied this canine model and found
that relatively modest levels of light ‘‘dramatically
accelerated the neurodegeneration.’’ It is well known
that visible light can cause photoreceptor cell death in
many animal species52 with light sensitivity especially
prominent in RHO mutants, experimentally produced
or naturally occurring, and ranging from Xenopus
laevis to mouse, rat, and dog. The possible deleterious
effect of environmental light exposure has also been
suggested in some RHO-adRP patients with an
altitudinal pattern of disease.53
The extreme light sensitivity of the canine T4R
RHO retina has been recently further characterized,
and a new light-damage paradigm developed to better
understand the degenerative process of rods, and to
enable rapid assessment of novel therapeutic strate-
gies in this large animal model. Following acute (1-
minute) exposure to white light (1 mW/cm2 corneal
irradiance, ~1590 lux), ultrastructural alterations of
rod outer segment discs were seen within 15 minutes,
followed by severe disruption of rod inner segment
integrity within 6 hours.54 TUNEL assay, which was
used to examine cell death, showed the first events of
rod loss to begin at 6 hours and to peak by 24 hours
postlight exposure. The effect of a 1-minute exposure
to light (0.1–1.0 mW/cm2) on photoreceptor loss was
recently found to be dose dependent, and the
threshold for causing light-induced rod death to be
between 0.1 and 0.2 mW/cm2 (170–320 lux).55 Two
weeks following exposure to a ‘‘middose’’ of light (0.5
mW/cm2), there was approximately a 50% loss of the
outer nuclear layer (ONL) in the tapetal region of
heterozygous mutant dogs, which was more severe at
6 and 36 weeks postexposure, suggesting a slower yet
ongoing process.55,56 Thus, exposure to this ‘‘mid-
dose’’ light intensity may be used to assess whether
therapeutic intervention, delivered after the degener-
ation has been triggered, can stall the progression of
degeneration. With the highest dose of light (1 mW/
cm2), there was at 2 weeks postexposure extensive rod
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photoreceptor cell death in the central to midper-
ipheral retina with an ONL limited to a single row of
cones, and activation of Mu¨ller cell gliosis.56 This
‘‘high-dose’’ light damage setting could therefore
provide a way of rapidly (within a couple of weeks)
assessing the beneficial effect of therapeutic interven-
tion preventing degeneration. In summary, a light-
damage paradigm that uses short exposure to a range
of white light intensities that are not themselves toxic
to retinas of WT animals, causes substantial acute and
progressive loss of rod cells in the outer nuclear layer
of the central to midperipheral zones of the T4R
RHO retina. Outcome measures of structural integrity
using both in vivo retinal imaging and histomorpho-
metric methods have been established. Functional
assessment may include electroretinography, but
novel methods for assessing visual behavior need to
be developed. Indeed, the use of an obstacle
avoidance course to test both rod- and cone-mediated
vision failed to show any impairment in T4R RHO
mutant dogs exposed to the highest dose of light
damage. Retention of far peripheral rods, and central
cones (in particular in the fovea-like area) likely
supports sufficient vision for mutant dogs to success-
fully complete this psychophysical test.54
With this clinically relevant large animal model in
hand, an National Institutes of Health–funded
consortium of investigators from the Schools of
Veterinary Medicine (Aguirre, Beltran) and Medicine
(Cideciyan, Jacobson) at the University of Pennsyl-
vania, and at the University of Florida (Hauswirth,
Lewin) was set up to develop and test a gene therapy
for RHO-adRP. As a strategy that could provide a
treatment for all RHO mutations irrespective of their
mechanism of action, the investigators opted to
develop an allele-independent knockdown and re-
placement approach. This gene therapy strategy
requires the following: (1) inhibition of the expression
of both the normal (WT) and the mutant alleles of
RHO, and (2) replacement of endogenous RHO
expression with a copy of the normal RHO gene,
which is made resistant to siRNA or ribosome
degradation through silent mutations. After screening
various knockdown reagents (including ribozymes
and shRNAs) both in vitro and in vivo in WT dogs,
an optimal shRNA (shRNA820) that substantially
reduced expression of endogenous RHO levels (both
at the RNA and protein levels) in WT and T4R RHO
mutant dogs was identified. Following validation of
this lead shRNA820, a resistant human RHO cDNA
was developed (RHO820). An in vitro assay confirmed
that shRNA820 did not reduce levels of RHO820
protein expression.
The efficacy of a combination virus that contained
both shRNA820 and RHO820 (scAAV2/5-HOP-
RHO820-H1-shRNA820) was tested in T4R RHO
mutant dogs. Subretinal injection (titer: 5 3 1011
vector genomes/mL) under infrared illumination was
shown to prevent damage from single or repeated
light exposures (1 mW/cm2) that, in the untreated
animal, cause end-stage retinal degeneration.55,56
Expression of human RHO820 was associated with
both retention of normal ONL thickness, and rod
outer segment structure after light exposure. Animals
that were repeatedly light exposed had preservation of
photoreceptors in the treated area and sustained rod-
mediated ERG function in the AAV-injected eyes
while balance sat solution–injected eyes showed
severely reduced ONL thickness and electroretino-
gram amplitudes (see Note added in proof before
Reference section).
Conclusions and Future Directions
 The RHO dog is a large animal model that
recapitulates features of Class B RHO mutations
seen in the human.
 The model is extremely light sensitive allowing for
a rapid assessment of a therapeutic intervention.
 A single vector with dual function (knockdown
and replacement) can prevent onset of rod loss
and preserve rod and cone function.
The question now remains—can a similar strategy
rescue rods in degenerating retinas of the human?
Preclinical Gene Therapy
Development for Leber Congenital
Amaurosis Caused by NPHP5
Mutations
Dr. Gustavo D. Aguirre
Abstract: Leber congenital amaurosis (LCA) poses a
therapeutic challenge given that there is early, severe
visual deficit or blindness, and there is an overlap
between normal development and early degeneration
of photoreceptor cells. To develop therapies for
eventual translation to the clinic, we have used the
canine NPHP5 (IQCB1) model where a C-terminal
truncation causes a photoreceptor ciliopathy with
early onset and rapid degeneration. By 6 weeks of age,
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electroretinogram (ERG) rod responses are markedly
reduced in amplitude or absent and cone responses
are not recordable. The absence of cone function
correlates with the lack of cone outer segments even
though there is preservation of cone inner segments.
To examine therapeutic approaches, we used adeno-
associated virus (AAV) vectors for gene augmenta-
tion. We injected subretinally in one eye AAV vectors
with hIRBP or hGRK1 promoters and the therapeu-
tic transgene. The fellow eye served as the untreated
control. Photoreceptor structure and function were
quantified by spectral-domain optical coherence
tomography and full-field ERGs. Visual behavior
was assessed at 1 year or later after treatment using an
obstacle-avoidance course to test separately the
treated and contralateral control eyes. Treatment at
5 to 6 weeks of age resulted in remarkable recovery of
cone function and preservation of rod ERG and
vision for the 1þ year observation time period.
Treatment blebs were associated with a significantly
retained photoreceptor layer. Treatment at 13 weeks
of age, an age at which all cones have lost their inner
and outer segments and rod outer segments are
degenerated in the affected animals, showed rapid
recovery of rod and cone function by 8 weeks after
treatment as well as preservation of function and
vision for at least 1 year. Our results show that, in
spite of the very severe and rapidly progressive
photoreceptor degeneration in mutant dogs, AAV-
mediated gene augmentation restores rod and cone
function and preserves retinal structure and vision
long term. These positive preclinical studies suggest a
path forward for translating this treatment approach
to the clinic.
Much progress has been made in the last few years
in moving from gene discovery to gene therapy. For
example, proof of concept studies for Leber congen-
ital amaurosis (LCA), achromatopsia and X-linked
retinitis pigmentosa were first done in canine models,
and subsequently in mouse disease models. Best
disease and now, LCA due to NPHP5 mutations,
have been described in the dog. These pathologies
have the same general features as in the human. It is
particularly fortunate to have canine models of these
diseases since they are viewed favorably by the Food
and Drug Administration as models for assessing
efficacy and safety in preclinical testing.
Defects in the NPHP5 (IQCB1) gene are known
to cause an early onset, severe form of retinal
degeneration within the LCA group of dystrophies
(NPHP5-LCA). The disease is a ciliopathy in which
defects are present in the photoreceptor connecting
cilium, a critical transition zone for passing soluble
and membrane components from inner segments to
outer segments. Mutations in NPHP5 are also
found in Senior Loken Syndrome (SLSN) in which
there is cystic kidney disease (nephronophthisis,
NPHP) as well as LCA. Ciliopathies, such as those
caused by CEP290 and RPGR mutations, have been
extensively reviewed and a framework has been
proposed to investigate aspects of cilial development
and pathology.57 In 2013,58 we described an
aggressive, early-onset canine retinal ciliopathy in
the Pit Bull Terrier caused by a single nucleotide
insertion in exon 10 of the NPHP5 gene. This
causes a premature stop that truncates the C-
terminus of the native protein. Clinically, this
results in several signs including early-onset retinal
degeneration, nystagmus and widely dilated pupils.
The condition is characterized by abnormal photo-
receptor cell development with concurrent, early,
and progressive degeneration.59 Disease pathology
in the dog was found to parallel and recapitulate
that seen in clinical testing of human patients. This
includes an NPHP5 mutation with early loss of rods
but relative retention of central retinal cone
photoreceptors cells although lack of function in
these cells was documented (Figs. 4A, 4B). In the
canine model by 6 weeks of age, rod responses as
measured by electroretinogram (ERG) are markedly
reduced in amplitude or fully absent; cone responses
are not recordable. The absence of cone responses is
due to a lack of cone outer segments; cone cell
bodies and inner segments are present but, simply,
outer segments fail to form.
With this knowledge, the dog NPHP5-LCA
model appeared to be suitable for preclinical studies
on gene replacement therapy. To begin this process,
we modified a subretinal injection device originally
developed for human applications, and now used in
dogs.60 This was the RetinaJet Subretinal Cannula
from SurModics, Inc. (product no longer manufac-
tured). This device has the advantage of not needing
surgical dissection, leading to a ‘‘shorter procedure
time and milder postoperative conjunctival swell-
ing.’’ In the LCA-NPHP5 dog, we injected the
NPHP5 transgene, using AAV5, scAAV8Y733F vec-
tors with interphotoreceptor retinoid-binding pro-
tein (IRBP) and hGRK1 promoters. We thought it
appropriate to target treatment to the fovea-like
region of the dog retina (as described in this review
by Dr. Beltran). Cideciyan et al.61 have previously
demonstrated from studies in human patients that
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NPHP5-LCA is an excellent candidate for ‘‘cone-
directed gene augmentation therapy’’ (Fig. 4A). We
also found that not all gene therapy approaches are
effective in that choice of vector was critical in
achieving positive results.
Treatment using the vector AAV2/5-IRBP-
cNPHP5 in 7.5-week-old dogs at a titer of 1.5 3
1011 vector genomes/mL did not rescue retinal
function when assessed up to 33 weeks after
treatment. A 10-fold increase in titer and treatment
at an earlier age resulted in improved retinal rod and
cone function. In contrast, treatment at 6 weeks with
scAAV2/8(Y733F)-hGRK1-cNPHP5 vector at a
comparable titer resulted in functional recovery
comparable to the higher dose of AAV2/5-hIRBP-
cNPHP5 vector (Fig. 4C). Furthermore, raising the
dose 10-fold led to excellent recovery of cone
function, preservation of cone and rod ERGs as
well as functional vision measured up to 1.3 years
after treatment (Aguirre GD, et al. IOVS
Figure 4. NPHP5 disease phenotypes and response to gene therapy. (A1) ONL thickness topography of NPHP5 patient shows the
distribution of the detectable photoreceptors to be limited to a central ellipse corresponding to the cone-dominant region, and more
peripherally corresponding to the rod-dominant region. Wide annular region shows no detectable photoreceptors (black). (A2) Cross-
sectional OCT scans along the vertical meridian through the fovea, extending 158 into superior (S) and inferior (I) retina in a healthy
subject (age 30 years; top) and NPHP5-LCA patient P4 (age 13 years). Magnified views of the central retina (right; white rectangles) with
overlapping longitudinal reflectivity profiles (LRP). Photoreceptor nuclear layer (ONL) is highlighted in blue; ellipsoid zone is highlighted
in yellow. OLM, outer limiting membrane; COS, cone outer segments; RPE/BrM, retinal pigment epithelium/Bruch’s membrane. In the
patients, there are wide hyperscattering bands (Sþ) and more narrow hyposcattering bands (S) distal to the ONL (far right along image).
Icon (upper left) is location of the scans on a retinal schematic. (B) Pseudocolor maps of ONL thickness topography (upper) in a 35-week-
old control dog (left) and an NPHP5-mutant (right) at 33 weeks of age. Insets, near-infrared reflectance images. Arrows on the maps
localize the reconstituted OCT scans (lower) along a superior–inferior meridian crossing the central visual streak at the gaps of the lines.
ONL on reconstituted scans is highlighted in blue and location of the scan relative to the vertical arrows is shown with a white wedge. All
eyes shown as equivalent right eyes and optic nerve, major blood vessels (black) and tapetum boundary (yellow) are overlaid for ease of
orientation. T, temporal; N, nasal retina. (C1) Right eye of a 5.7-week-old vector-treated NPHP5 mutant with large subretinal bleb that
encompasses the fovea-like central region. (C2) Six-week-old NPHP5 mutant dog retina showing that most cones lack an outer segment
(red ¼ hCAR labeling; arrows indicate present cone outer segments); rod outer segments (green ¼ rod opsin labeling) form, but are
abnormal and there is extensive rod opsin mislocalization to the ONL. (C3) Treatment at 5.7 weeks with AAV-cNPHP5 vector (red traces¼
treated eye; black traces¼untreated fellow eye) results in robust recovery rod, mixed rod-cone and cone ERG responses by 13 weeks. Fig.
A1 modified and reprinted with permission from Cideciyan AV, Rachel RA, Aleman TS, et al. Cone photoreceptors are the main targets for
gene therapy of NPHP5 (IQCB1) or NPHP6 (CEP290) blindness: generation of an all-cone Nphp6 hypomorph mouse that mimics the
human retinal ciliopathy. Hum Mol Genet 2011; 20:1411–1423. Figs. B, C2, and C3 modified and reprinted with permission from Downs
LM, Scott EM, Cideciyan AV, et al. Overlap of abnormal photoreceptor development and progressive degeneration in Leber congenital
amaurosis caused by NPHP5 mutation. Hum Mol Genet 2016;25:4211–4226.
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2016;57:ARVO E-Abstract 2293). This therapy
allowed for retention of a significant number of
photoreceptor nuclei but there was thinning long
term. It was also apparent that early treatment
resulted in longer lasting structural and functional
rescue. Thus, further vector and promoter optimiza-
tion will be needed to ensure a permanent treatment
modality.
Conclusions and Future Directions
 An NPHP5 exon 10 insertion in dogs results in an
early-onset, aggressive LCA-ciliopathy, similar to
that seen in the human.
 Most cone outer segments fail to form during
development; thus, cone function is absent. Rod
outer segments develop but they are abnormal.
There is early loss of rod function indicating
dissociation of structure and function.
 The mutant NPHP5 protein permits rod outer
segment formation, albeit abnormal. Failure of
cone outer segments to form suggests that the
functional domains and role(s) of NPHP5 in the
rod and cone sensory cilium are not identical in
each photoreceptor class.
 Following gene therapy, cone outer segments
form and function is restored. Rod structural
abnormalities are reversed and structure and
function are preserved.
The following three pending questions remain: (1)
identification of optimal vector promoter for transla-
tional therapies; (2) achieving long-term stability and
efficacy of the treatment, and (3) can we treat more
advanced disease stages and what are the structural
and functional outcomes?
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